Russell Investments Group Ltd. Buys 34,635 Shares of Ultragenyx Pharmaceutical Inc. $RARE

Key Points

• Russell Investments Group Ltd. increased its holdings in Ultragenyx Pharmaceutical by 50.1% during the first quarter, acquiring an additional 34,635 shares.
• A number of institutional investors, including GAMMA Investing LLC and Covestor Ltd., also increased their stakes in Ultragenyx Pharmaceutical in the same period, highlighting growing investor interest.
• Analysts have set a new average target price of $81.50 for Ultragenyx Pharmaceutical, with a consensus rating of "Moderate Buy" after several research updates.

Russell Investments Group Ltd. raised its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 50.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 103,822 shares of the biopharmaceutical company's stock after purchasing an additional 34,635 shares during the period. Russell Investments Group Ltd. owned 0.11% of Ultragenyx Pharmaceutical worth $3,759,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in RARE. GAMMA Investing LLC boosted its holdings in shares of Ultragenyx Pharmaceutical by 76.2% during the 1st quarter. GAMMA Investing LLC now owns 747 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 323 shares during the last quarter. ANTIPODES PARTNERS Ltd bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $57,000. Headlands Technologies LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 1st quarter valued at about $59,000. Covestor Ltd boosted its holdings in shares of Ultragenyx Pharmaceutical by 86.8% during the 1st quarter. Covestor Ltd now owns 1,711 shares of the biopharmaceutical company's stock valued at $62,000 after purchasing an additional 795 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter valued at about $82,000. Institutional investors own 97.67% of the company's stock.

Ultragenyx Pharmaceutical Stock Performance

NASDAQ RARE traded up $0.22 during trading on Thursday, hitting $30.30. The stock had a trading volume of 1,033,956 shares, compared to its average volume of 1,555,903. The stock has a market capitalization of $2.92 billion, a price-to-earnings ratio of -5.48 and a beta of 0.25. Ultragenyx Pharmaceutical Inc. has a one year low of $25.81 and a one year high of $60.37. The stock has a 50 day simple moving average of $31.11 and a 200 day simple moving average of $35.36.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $0.10. The business had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The firm's quarterly revenue was up 13.2% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on RARE shares. Canaccord Genuity Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a report on Friday, August 8th. Cantor Fitzgerald lowered their price target on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a report on Wednesday, August 6th. Guggenheim reaffirmed a "buy" rating and issued a $64.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, June 20th. Wedbush lowered their price target on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a report on Monday, July 14th. Finally, HC Wainwright raised shares of Ultragenyx Pharmaceutical to a "buy" rating and set a $80.00 price target for the company in a report on Monday, July 28th. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of "Moderate Buy" and a consensus price target of $81.50.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the firm's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $37.39, for a total value of $89,922.95. Following the completion of the sale, the director owned 15,344 shares of the company's stock, valued at $573,712.16. This trade represents a 13.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 5.50% of the stock is currently owned by insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.